Literature DB >> 18313310

Proteasome inhibition by peptide-semicarbazones.

Johann Leban1, Marcus Blisse, Babett Krauss, Sandra Rath, Roland Baumgartner, Markus H J Seifert.   

Abstract

Peptide-semicarbazones derived from Z-Trp-Trp-Phe-aldehyde inhibit the chymotryptic activity of the human proteasome at nanomolar concentrations, but are less active in a NFkappaB reporter gene assay. Cyclic semicarbazones, in contrast, combine a strong inhibitory effect on the enzyme with an inhibition of NFkappaB signaling in the nanomolar range. In addition, a practical synthesis for scale-up of such compounds was developed.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18313310     DOI: 10.1016/j.bmc.2008.02.042

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  5 in total

Review 1.  Proteasome inhibitors: an expanding army attacking a unique target.

Authors:  Alexei F Kisselev; Wouter A van der Linden; Herman S Overkleeft
Journal:  Chem Biol       Date:  2012-01-27

2.  Structure-Activity Relationship of Semicarbazone EGA Furnishes Photoaffinity Inhibitors of Anthrax Toxin Cellular Entry.

Authors:  Michael E Jung; Brian T Chamberlain; Chi-Lee C Ho; Eugene J Gillespie; Kenneth A Bradley
Journal:  ACS Med Chem Lett       Date:  2014-01-21       Impact factor: 4.345

Review 3.  Computational Approaches for the Discovery of Human Proteasome Inhibitors: An Overview.

Authors:  Romina A Guedes; Patrícia Serra; Jorge A R Salvador; Rita C Guedes
Journal:  Molecules       Date:  2016-07-16       Impact factor: 4.411

4.  NF-κB Pathway as a Potential Target for Treatment of Critical Stage COVID-19 Patients.

Authors:  Ralf Kircheis; Emanuel Haasbach; Daniel Lueftenegger; Willm T Heyken; Matthias Ocker; Oliver Planz
Journal:  Front Immunol       Date:  2020-12-10       Impact factor: 7.561

5.  Synergistic Antivascular and Antitumor Efficacy with Combined Cediranib and SC6889 in Intracranial Mouse Glioma.

Authors:  Merryl R Lobo; Ayaka Kukino; Huong Tran; Matthias C Schabel; Charles S Springer; G Yancey Gillespie; Marjorie R Grafe; Randall L Woltjer; Martin M Pike
Journal:  PLoS One       Date:  2015-12-08       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.